Naphthalimides
"Naphthalimides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.
Descriptor ID |
D053644
|
MeSH Number(s) |
D02.478.480 D03.383.621.808.612 D03.438.531.460 D04.615.638.596
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naphthalimides".
Below are MeSH descriptors whose meaning is more specific than "Naphthalimides".
This graph shows the total number of publications written about "Naphthalimides" by people in this website by year, and whether "Naphthalimides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1988 | 0 | 1 | 1 | 1991 | 0 | 1 | 1 | 1993 | 0 | 1 | 1 | 1994 | 0 | 2 | 2 | 1995 | 0 | 2 | 2 | 1996 | 0 | 1 | 1 | 1999 | 0 | 1 | 1 | 2000 | 0 | 1 | 1 | 2001 | 0 | 1 | 1 | 2010 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Naphthalimides" by people in Profiles.
-
Alcala MA, Kwan SY, Shade CM, Lang M, Uh H, Wang M, Weber SG, Bartlett DL, Petoud S, Lee YJ. Luminescence targeting and imaging using a nanoscale generation 3 dendrimer in an in vivo colorectal metastatic rat model. Nanomedicine. 2011 Jun; 7(3):249-58.
-
Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 2001 Apr; 29(4 Pt 2):596-600.
-
Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
-
Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
-
Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101.
-
Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss AP. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
-
Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
-
Mick R, Ratain MJ. Bootstrap validation of pharmacodynamic models defined via stepwise linear regression. Clin Pharmacol Ther. 1994 Aug; 56(2):217-22.
-
Mullane MR, Schilsky RL, Carroll RB, Wade JL, Kilton LJ, Blough RR, Bauman A, French SL, Benson AB. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(3):267-70.
-
Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|